CytomX released expanded cohort results from its Phase 1 study of Varsetatug masetecan (Varseta‑M), a masked EpCAM-directed antibody–drug conjugate, reporting an objective response rate of about 32% at the 10 mg/kg dose in advanced colorectal cancer and progression‑free survival near 7 months. The company said responses were durable in a heavily pretreated population and that adverse events—chiefly diarrhea—were generally manageable with prophylaxis. BioCentury and market reports noted the data underpin CytomX’s plan to discuss registrational strategy with the FDA and to test the agent as a potential monotherapy in later‑line settings. Investors reacted positively, lifting CytomX shares on the clinical update.